References and Links to Papers
DIAGNOSTIC POTENTIAL OF THE NMDA RECEPTOR PEPTIDE ASSAY FOR ACUTE ISCHEMIC STROKE
Jul 27, 2012
The acute assessment of patients with suspected ischemic stroke remains challenging. The use of brain biomarker assays may improve the early diagnosis of ischemic stroke. The main goal of the study was to evaluate whether the NR2 peptide, a product of the proteolytic degradation of N-methyl-D-aspartate (NMDA) receptors... read more
NR2 AB: RISK ASSESSMENT OF TIA/STROKE IN PATIENTS WITH HISTORY OF ISOLATED AND MULTIPLE CEREBROVASCULAR EVENTS
Jan 15, 2011
Predicting stroke using biomarkers would enable clinicians to help prevent stroke or mitigate damage. Several stroke biomarkers have been investigated but none has shown near term predictive value.
We studied patients presenting with a history of stroke or transient ischemic attack (TIA) to determine whether serum levels of autoantibodies to the NMDA receptor NR2 peptide... read more
GFAP AND AB AGAINST NMDA RECEPTOR SUBUNIT NR2 AS BIOMARKERS FOR ACUTE CEREBROVASCULAR DISEASES
Jun 17, 2015
We studied whether the serum levels of glial fibrillary acidic protein (GFAP) and of antibodies against the N-methyl-d-aspartate receptor subunit NR2 (NR2 RNMDA ) can discriminate between intracerebral haemorrhage (ICH) and ischaemic stroke (IS) in stroke patients... read more
CIS Biotech, Inc. is focused on bringing to the marketplace In-Vitro Diagnostic Tools to improve laboratory assessment of Stroke or Brain Attack.